Comparative Study of Anti-Hypertensive Drugs (Beta-Blockers)

Hypertension remains a leading risk factor for cardiovascular diseases globally.Beta-blockers have been a cornerstone in antihypertensive therapy.This study aims to compare the efficacy, safety, and pharmacological profiles of various beta-blockers, including first, second, and third generations, in the management of hypertension. Classification of Beta-BlockersBeta-blockers are classified into three generations based on their pharmacological properties: First Generation: Non-selective 1 and 2 blockers (e.g., Propranolol, Nadolol) Second Generation: Cardioselective 1 blockers (e.g., Metoprolol, Atenolol) Third Generation: Non-selective blockers with additional vasodilatory properties (e.g., Carvedilol, Nebivolol) Comparative EfficacyA meta-analysis of 26 randomized controlled trials involving 19,170 patients assessed the impact of beta-blockers on mortality in heart failure patients.The study found a significant reduction in all-cause mortality with beta-blocker use, irrespective of heart failure etiology.Comparative studies between nebivolol and other antihypertensive agents revealed that nebivolol was associated with a higher risk of stroke compared to ACE inhibitors and thiazide diuretics.